Tag: FDA clearance

All

The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.

Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.